Sanofi (SANF) Plunged -0.31% on Feb 15

February 15, 2018 - By Vivian Park

Shares of Sanofi (BIT:SANF) last traded at 63.7, representing a move of -0.31%, or -0.2 per share, on volume of 293 shares. After opening the trading day at 63.73, shares of Sanofi traded in a close range. Sanofi currently has a total float of 1.24 billion shares and on average sees 1,411 shares exchange hands each day. The stock now has a 52-week low of 63.51 and high of 90.15.

FTSE MIB: A Growing European Index

Italy is known worldwide not just for being a country with a rich culture and heritage but most importantly, for being a nation with a competent trade and commerce conduct. It lures Sanofi to its market. That being said, it is surely one of the biggest assets of the European economy.

Having been tested through the toughest of times, there is so much to learn from the economy of Italy. Through the years, Italy and its equity market in particular, has helped shape Europe as a successfully thriving region.

The Italian Equity Market

The Italian equity market dates back as early as the 1800s. The Borsa Italiana or Piazza Affari, the main Italian stock exchange, had been founded as one of the earliest European stock exchanges in February 1808 by Viceroy of the Napoleonic Kingdom of Italy Eugène de Beauharnais.

The Borsa Italiana boasts as one of the few stock exchanges with the longest trading hours. The pre-market session begins at 8:00 a.m. and ends at 9:00 a.m. The regular session immediately follows at 9:00 a.m. and ends at 5:30 p.m. There is also a post market session that begins at 6:00 p.m. and ends at 8:30 p.m. These long trading hours provide flexible opportunities for international investors to buy and sell stocks on and from the Borsa Italiana. This is one of the reasons that Italy has one of the most successful trade and commerce environments in the world. Many investors are looking for reliable companies like Sanofi there.

The FTSE Milano Italia Borsa (MIB) is the free-float market-capitalization-weighted index that monitors the 40 most actively traded stocks on the Borsa Italiana. Until June 2009 when the FTSE had started operating the FTSE MIB, the S&P had operated it as the S&P/MIB.

Roughly 80% of the overall market valuation on the Borsa Italiana is included in the FTSE MIB, making it a significant economic indicator not just in Italy but in the entire European region. The FTSE MIB is rebalanced four times a year in order to maintain clear representation of the national economy. Sanofi stocks are carefully checked by professionals.

Milestones through the Years

The Borsa Italiana had always been operated as a public entity until it was privatized in 1998. The London Stock Exchange Group had then bought it in an all-stock transaction in 2007, consolidating the Borsa Italiana and the London Stock Exchange.

Hundreds of years after its foundation, the Borsa Italiana now has an overall market valuation of about $650 billion with over 340 stocks listed on it.

Meanwhile, the FTSE MIB had posted its all-time high of 50,108.56 points in March 2000; and its all-time low of 12,362.50 points in July 2012. The meltdown in 2012 is widely attributed to the financial crisis in Spain, which had affected other European nations; and to the heightened borrowing costs in Europe.

Investing on Borsa Italiana stocks is ideal today not just for domestic investors but also for international investors. Evidently, many investors are flocking the Italian equity market to take advantage of a compelling borrowing environment.

More notable recent Sanofi (BIT:SANF) news were published by: Seekingalpha.com which released: “Sanofi: Opportunity On Irrational Valuation” on February 14, 2018, also Cnbc.com with their article: “Sanofi pins hopes on 2018 for growth after recent takeover deals” published on February 07, 2018, Marketwatch.com published: “Sanofi and SK Chemicals sign flu vaccine deal” on February 12, 2018. More interesting news about Sanofi (BIT:SANF) were released by: Nytimes.com and their article: “Sanofi, Facing Threat From Generics, Moves to Buy Hemophilia Drug Maker” published on January 22, 2018 as well as Bostonglobe.com‘s news article titled: “Sanofi Genzyme lays off 130 at Allston Landing plant” with publication date: February 07, 2018.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of 79.08 billion EUR. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 9.49 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Park

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: